In another retrospective analysis of patients with RA, serum drug levels of IFX and ADA (Fc-containing TNFis) at six months were significantly lower in patients who had higher RF levels at baseline compared with those with lower RF levels, while CZP levels remained consistent across baseline RF levels [29]. This evidence concerns the gene ADA and rheumatoid arthritis.